





**1 September 2015**

Daily news and comments on the Life Sciences Sector in **Australia** by The Daily Molecule, part of Van Leeuwenhoek Institute

Companies in Today's newsletter:

- AVITA MEDICAL (ASX:AVH, OTC:AVMXY)
- BIONOMICS (ASX:BNO, ADR:BMICY)



	<b>1 Sept 2015</b>	<b>1 mth</b>	<b>3 mth</b>	<b>1yr</b>	<b>YTD</b>
ASX All Ordinaries	5,222.10	-6.5%	-8.7%	-7.6%	-3.7%
Nasdaq Biotech Index	3,597.71	-6.4%	-4.7%	26.4%	13.9%
Nasdaq Index	4,274.58	-5.3%	-6.0%	2,5%	0.6%
Dow Jones Index	16,528.03	2.0%	0.3%	-2.9%	1.2%
Euro STOXX 50	3,269.63	-3.6%	-6.7%	2.3%	-5.7%



**AVITA MEDICAL (ASX:AVH, OTC:AVMXY)**

**PRICE: AUD 0.077 (+6.9%)**

Avita Medical has been given a high rating to its proposal to a U.S. federal body exploring the possible use of ReCell under a disaster preparedness program. BARDA and AMCG informed the Company that they have completed their technical evaluation of the Company's proposal that was submitted on July 24<sup>th</sup>. BARDA is a U.S. federal agency assigned to ensure the United States is well prepared for public health emergencies. The original formal public solicitation that Avita responded to indicated that BARDA is seeking to fund late-stage development and procurement of autograft-sparing products that can enhance the capacity to provide definitive care for thermal burn injuries. BARDA utilizes a competitive bidding process and the awarding of, or timing for, a contract under this solicitation remains uncertain. ReCell is Avita Medical's proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES) using a small sample of the patient's skin. RES is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

**BIONOMICS (ASX:BNO, ADR:BMICY)**

**PRICE: AUD 0.40 (-2.4%)**

Bionomics announced that its BNC101 investigational new drug application (IND) submission to the US Food and Drug Administration has been accepted. Bionomics plans to initiate a Phase I clinical trial in patients with metastatic colon cancer and in patients with metastatic pancreatic cancer prior to 31 December 2015. BNC101 is a first-in-class, high affinity anti-LGR5 humanized monoclonal antibody targeting cancer stem cells. LGR5 is a receptor overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumors. The Phase I trial will aim to demonstrate that BNC101 is safe and well tolerated as well as that it is able to delay disease relapse in treated patients. Initial indications will be metastatic colorectal cancer and metastatic pancreatic cancer. Development will occur initially as a combination therapy with standard of care chemotherapies while long term development strategies will evaluate BNC101 in monotherapy to prevent or delay tumour relapse. Further details will be provided upon commencement of the clinical trial. The global market for metastatic



colorectal cancer treatments has been predicted to grow to USD 9.4 billion by 2020. In 2015, the U.S. Center for Disease Control and Prevention, or CDC, estimates that there will be approximately 133,000 new cases of metastatic colorectal cancer in the United States. Currently, the five-year survival rate for metastatic colorectal cancer patients is approximately 11% with a median overall survival span for metastatic colorectal cancer ranging from approximately 20 to 30 months. LGR5 expression has been correlated with poor patient response or survival in metastatic colorectal cancer patients.

The global metastatic pancreatic cancer drug market is estimated to be USD 1.2 billion in 2015. In 2015, the CDC estimates that there will be approximately 49,000 new cases of metastatic pancreatic cancer in the United States. For pancreatic cancer patients overall, the five-year survival rate is approximately 7% for all stages combined and only 2% for patients with metastatic pancreatic cancer, according to the U.S. National Cancer Institute. Studies have found that the median overall survival span for metastatic pancreatic cancer patients ranges from approximately eight to 11 months. Although there are a number of approved drugs for the treatment of metastatic pancreatic cancer, there continues to be a significant unmet medical need.

*The Daily Molecule is a publication of Van Leeuwenhoeck Institute Inc*

**Marcel Wijma MSc**  
**CEO & Managing Director**

Van Leeuwenhoeck Research (US) Inc  
244 Fifth Avenue, Suite W204  
New York, NY, 10001 USA

Phone US: +1 917 460 6185  
Phone NL: +31 684 892 954

[m.wijma@leeuwenhoeck.com](mailto:m.wijma@leeuwenhoeck.com)  
[www.leeuwenhoeck.com](http://www.leeuwenhoeck.com)

# THE DAILY MOLECULE

YOUR EYES AND EARS ON THE GLOBAL BIOTECH MARKET

Company	Ticker	Price	Perf 1mth	Perf YTD	Perf 1 yr	Market cap
ACRUX	ACR.AX	0.630	-22.7%	-48.2%	-59.8%	104.90
ACTINOGEN	ACW.AX	0.052	-11.4%	-16.2%	244.4%	25.59
ADMEDUS	AHZ.AX	0.066	9.1%	-28.8%	-39.1%	95.21
ANTEO DIAGNOSTICS	ADO.AX	0.096	-9.5%	-20.8%	0.0%	81.10
ANTISENSE	ANP.AX	0.082	-18.2%	0.0%	-35.7%	13.24
AVITA MEDICAL	AVH.AX	0.077	-12.5%	-14.6%	-39.1%	25.05
BENITEC	BLT.AX	0.560	-38.0%	-37.6%	-42.5%	64.74
BIOTRON	BIT.AX	0.100	-11.8%	-7.6%	-20.5%	24.24
BIONOMICS	BNO.AX	0.400	-12.2%	-8.1%	-38.8%	167.00
CIRCADIAN	CIR.AX	0.200	0.0%	21.2%	7.5%	29.62
CYNATA	CYP.AX	0.450	-37.3%	38.2%	28.8%	27.72
CLINUVEL	CUV.AX	2.910	-8.5%	-8.5%	-9.1%	129.79
CELLMID	CDY.AX	0.032	12.9%	34.6%	20.7%	25.37
ELLEX MEDICAL LASERS	ELX.AX	0.385	6.7%	14.3%	-12.3%	41.45
IDT AUSTRALIA	IDT.AX	0.260	21.7%	86.7%	0.0%	49.71
IMPEDIMED	IPD.AX	1.040	31.1%	27.5%	304.2%	304.82
IMUGENE	IMU.AX	0.009	0.0%	10.0%	-21.4%	11.97
INVION GROUP	IVX.AX	0.018	-34.6%	-63.8%	-79.5%	14.81
MESOBLAST	MSB.AX	3.320	-1.2%	-11.1%	-7.5%	1052.77
NEUREN PHARM.	NEU.AX	0.087	12.0%	-31.1%	-7.0%	141.39
NOVOGEN	NRT.AX	0.150	-23.8%	53.8%	7.4%	63.60
ONCOSIL	OSL.AX	0.100	4.5%	33.7%	0.0%	35.53
ORTHOCELL	OCC.AX	0.570	125.0%	71.4%	100.0%	47.03
OSPREY MEDICAL	OSP.AX	0.730	25.8%	41.1%	51.0%	89.94
PHARMAXIS	PXS.AX	0.205	-2.3%	59.3%	241.3%	64.13
PHOSPHAGENICS	POH.AX	0.018	-28.0%	-76.0%	-81.6%	22.72
PHYLOGICA	PYC.AX	0.011	0.0%	-31.6%	8.3%	11.02
PRIMA BIOMED	PRR.AX	0.069	-17.2%	45.5%	14.3%	94.85
PRANA BIOTECH	PBT.AX	0.145	3.2%	-20.0%	-36.0%	70.89
PRESCIENT THERAPEUTICS	PTX.AX	0.080	0.0%	-41.8%	-41.8%	4.22
PSIVIDA	PVA.AX	5.340	11.0%	12.1%	15.6%	157.00
REGENEUS	RGS.AX	0.110	-9.4%	-9.4%	-49.1%	22.07
RESMED	RMD.AX	7.310	8.7%	15.4%	50.7%	10307.10
RHINOMED	RNO.AX	0.038	10.0%	17.9%	-23.3%	20.49
SIMAVITA	SVA.AX	0.500	-4.3%	19.5%	25.0%	46.13
SOMNOMED	SOM.AX	2.500	9.3%	9.3%	74.6%	127.35
STAR PHARMA	SPL.AX	0.575	-11.1%	22.4%	-9.9%	183.48
SUDA	SUD.AX	0.034	6.7%	-45.8%	-36.0%	33.46
TISSUE THERAPIES	TIS.AX	0.055	68.6%	-81.3%	-79.7%	14.48
UNIVERSAL BIOSENSORS	UBI.AX	0.360	35.6%	122.2%	128.6%	63.32
VIRALYTICS	VLA.AX	0.625	-8.5%	154.2%	167.9%	115.00

Source: Van Leeuwenhoeck Institute Inc



#### *Disclaimer*

*The facts stated and the opinion and prognoses given in this publication are based on data and information considered to be reliable and have been carefully worked into our analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness. Van Leeuwenhoek Institute does not accept responsibility or liability in any way in respect to the information stated herein.*

*Van Leeuwenhoek Institute does not hold or have positions in securities as referred to in this publication. The views expressed in this publication accurately reflect the analyst's personal views on the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Van Leeuwenhoek Institute is in any way related to the specific recommendations or views contained in this publication.*

*Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. The value of, or income from, any investments referred to herein may fluctuate and/or be affected by changes in exchange rates. Past performances are not indicative for future results. Investors should make their own investment decisions without relying on this publication.*

*Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuer or market discussed herein and other persons should not take any action on the basis of this publication.*

*Information, opinions or recommendations contained in this publication are submitted solely for advisory and information purposes. The information used and statements of fact made, have been obtained from sources considered reliable, but we neither guarantee nor represent the completeness or accuracy. Such information and the opinions expressed are subject to change without notice. This publication is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed.*

*Van Leeuwenhoek Institute does not accept any equity compensation. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence.*

*Periodic Research reports and research notes on this Company are available at our web site:*

[www.leeuwenhoek.com](http://www.leeuwenhoek.com)

© Copyright 2015 by Van Leeuwenhoek Institute Inc.